N@N

DVAX, DSCO, CYTR, CYTK, CYCC, CXM, Biomed - Genetics Stocks 5.48% undervalued

^{Published on 2011-01-26 12:42:30 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX), DISCOVERY LABORATORIES INC (NASDAQ:DSCO), CYTRX CORP (NASDAQ:CYTR), CYTOKINETICS INC (NASDAQ:CYTK), CYCLACEL PHARMACEUTICALS INC (NASDAQ:CYCC), CARDIUM THERAPEUTICS INC (AMEX:CXM) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     DVAX       DYNAVAX TECHNOLOGIES CORP           2.98           3.15           5.48% undervalued           Biomed - Genetics      
     DSCO       DISCOVERY LABORATORIES INC          0.36           2.6            86.16% undervalued          Biomed - Genetics      
     CYTR       CYTRX CORP                          0.8101         1.45           44.26% undervalued          Biomed - Genetics      
     CYTK       CYTOKINETICS INC                    1.88           4.3            56.24% undervalued          Biomed - Genetics      
     CYCC       CYCLACEL PHARMACEUTICALS INC        1.51           3.91           61.41% undervalued          Biomed - Genetics      
     CXM        CARDIUM THERAPEUTICS INC            0.388          1.21           67.87% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) - Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a preclinical vaccine, for the influenza prevention; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a preclinical autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline to discover, develop, and commercialize DV1179 and other novel TLR inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist products for asthma and COPD. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

DISCOVERY LABORATORIES INC (NASDAQ:DSCO) - Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants. The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

CYTRX CORP (NASDAQ:CYTR) - CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. The companys drug development pipeline includes clinical development of three product candidates for cancer indications, including three planned Phase II clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer, and soft tissue sarcomas; two Phase II proof-of-concept clinical trials with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia and patients with glioblastoma multiforme; and a registration study of tamibarotene for the treatment of acute promyelocytic leukemia. It also has molecular chaperone regulation program, which includes a planned Phase II clinical study of arimoclomol in amyotrophic lateral sclerosis and Phase I stage development of Iroxanadine for various potential indications. The company was founded in 1985 and is headquartered in Los Angeles, California.

CYTOKINETICS INC (NASDAQ:CYTK) - Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The companys lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The companys products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295. The company was founded in 1997 and is headquartered in South San Francisco, California.

CYCLACEL PHARMACEUTICALS INC (NASDAQ:CYCC) - Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancer and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with advanced solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

CARDIUM THERAPEUTICS INC (AMEX:CXM) - Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations. Its investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of therapeutic products for wound healing, bone repair, and cardiovascular indications. Its product candidates include Generx, a DNA-based angiogenic growth factor therapeutic that is in phase 3 clinical trail for the treatment of patients with advanced coronary artery disease; Excellarate, a tissue repairs product candidate that is in Phase 2b clinical trial for the treatment of non-healing, neuropathic diabetic foot ulcers; and Excellagen, which is completed Phase 2b clinical trial for the treatment of chronically non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net